Novartis and the Massachusetts Institute of Technology have launched a long-term research collaboration aimed at changing the way pharmaceuticals are produced.
Novartis will invest $65 million in research activities at MIT over the next 10 years.
The partnership, known as the Novartis-Massachusetts Institute of Technology (MIT) Center for Continuous Manufacturing, will work to develop new technologies that could replace the conventional batch-based system in the pharmaceuticals industry.
Development
The project will involve seven to 10 MIT faculty members, as well as students, postdoctoral fellows, MIT staff scientists, and Novartis engineers and scientists.
Research will be conducted primarily through MIT Ph.D. programs and then transferred to Novartis for further development to industrial-scale projects.
Dr Daniel Vasella, chairman and CEO, said: "This partnership demonstrates our commitment to lead not only in discovering innovative treatments for patients but also in improving manufacturing processes,
“Our collaboration with MIT, a worldwide leader in developing cutting edge technologies, holds the promise to achieve a quantum leap in the production of pharmaceuticals, a field which has received rather little attention in the past."
MIT officials believe the collaboration will be the largest academic research effort in the world focused on modernizing drug manufacturing.
October 3 2007
Related Links
Novartis
Bookmark with:
- Digg
- Reddit
- Del.icio.us
- Facebook
- Newsvine
Sign Up to Exec UK now for FREE!